These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 21315783)

  • 1. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
    Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
    Panka DJ; Liu Q; Geissler AK; Mier JW
    Mol Cancer; 2013 Mar; 12():17. PubMed ID: 23497256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Ko JS; Zea AH; Rini BI; Ireland JL; Elson P; Cohen P; Golshayan A; Rayman PA; Wood L; Garcia J; Dreicer R; Bukowski R; Finke JH
    Clin Cancer Res; 2009 Mar; 15(6):2148-57. PubMed ID: 19276286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
    Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
    J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.
    Finke JH; Rayman PA; Ko JS; Bradley JM; Gendler SJ; Cohen PA
    Cancer J; 2013; 19(4):353-64. PubMed ID: 23867518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
    Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H
    Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
    Cohen PA; Ko JS; Storkus WJ; Spencer CD; Bradley JM; Gorman JE; McCurry DB; Zorro-Manrique S; Dominguez AL; Pathangey LB; Rayman PA; Rini BI; Gendler SJ; Finke JH
    Immunol Invest; 2012; 41(6-7):680-710. PubMed ID: 23017141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
    Zhao Q; Guo J; Wang G; Chu Y; Hu X
    Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
    Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
    Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
    Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.
    Abe F; Younos I; Westphal S; Samson H; Scholar E; Dafferner A; Hoke TA; Talmadge JE
    Int Immunopharmacol; 2010 Jan; 10(1):140-5. PubMed ID: 19833232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
    Finke JH; Rini B; Ireland J; Rayman P; Richmond A; Golshayan A; Wood L; Elson P; Garcia J; Dreicer R; Bukowski R
    Clin Cancer Res; 2008 Oct; 14(20):6674-82. PubMed ID: 18927310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.
    Hamilton MJ; Banáth JP; Lam V; Lepard NE; Krystal G; Bennewith KL
    Cancer Immunol Immunother; 2012 May; 61(5):643-54. PubMed ID: 22021068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.